Tissue Engineering and Regenerative Medicine 2025 – Quo Vadis?

Tissue Engineering and Regenerative Medicine aim at repairing or regenerating tissues and even whole organs, which are lost or deteriorated for any reason, including aging, degenerative diseases, trauma or surgery. Such an endeavor requires by definition the integration of multi-disciplinary expertise and approaches. The building blocks of this expanding field of research span from fundamental to translational to preclinical, such as stem and progenitor cell biology, immunology, biomaterial science, engineering and additive manufacturing (3D printing). The resulting translational approaches span from classic combinations of progenitors with biomaterial scaffolds to cell therapy, gene therapy and the use of exosomes/extracellular vesicles or bioactive molecules, as well as their various combinations. Applications in the field are increasingly expanding also to the generation of in vitro 3D models of healthy and diseased tissues, to provide more physiological platforms for biological investigations and high-throughput drug screening.

Inspired by the recent gathering of many thought leaders at the European meeting of the Tissue Engineering and Regenerative Medicine International Society (TERMIS) in Freiburg (Germany), in this Research Topic we would like to collect a snapshot of the current state-of-the-art in this field with a view over the up-and-coming developments, in the form of a collection of Mini-Reviews by invitation only. The Topics will cover as broadly as possible the different constitutive aspects of the field.

Please note that this is an invitation-only Research Topic. Manuscripts submitted by non-invited authors will be processed as general submissions and will not be included in this Research Topic. All contributions will undergo peer review and must meet the journal’s standards for scientific rigor and impact.

Dr. Johannes Grillari is a co-founder, shareholder, scientific advisor of Evercyte GmbH, TAmiRNA GmbH, Phoenestra GmbH, Rockfish Bio AG.
Dr. Mikaël M Martino is the CSO of Myostellar and Orio Therapeutics.